リンパ腫治療薬市場：治療法別、エンドユーザー別-2023-2030年の世界予測

リンパ腫治療薬の世界市場は、2023年に92億3,555万米ドル、CAGR14.11%で大きく成長し、2030年には233億7,127万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のリンパ腫治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.リンパ腫治療薬の世界市場規模および予測は？

2.予測期間中、世界のリンパ腫治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.リンパ腫治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.リンパ腫治療薬の世界市場における競争戦略は？

5.リンパ腫治療薬の世界市場における技術動向と規制の枠組みは？

6.リンパ腫治療薬の世界市場における主要ベンダーの市場シェアは？

7.リンパ腫治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • さまざまな種類のがんの罹患率の上昇
    • 免疫チェックポイント阻害剤やキイトルーダなどのプレミアム製品の採用が増加
    • いくつかの新しい治療法が最近承認されました
  • 抑制要因
    • 高額な治療費
  • 機会
    • 共同プロモーションと商品化の増加
    • 研究開発の実践における大幅な成長
  • 課題
    • 医薬品の特許が切れる
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 リンパ腫治療薬市場治療別

• 化学療法
• 免疫療法
  • キメラ抗原受容体T細胞療法
  • 免疫チェックポイント阻害剤
  • モノクローナル抗体
• 放射線治療
• 幹細胞または骨髄移植
• 手術
• 標的療法

第7章 リンパ腫治療薬市場：エンドユーザー別

• 外来手術センター
• クリニック
• 病院

第8章 南北アメリカのリンパ腫治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のリンパ腫治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのリンパ腫治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第12章 掲載企業一覧

第13章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. LYMPHOMA THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. LYMPHOMA THERAPEUTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. LYMPHOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
• FIGURE 5. LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
• FIGURE 6. LYMPHOMA THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. LYMPHOMA THERAPEUTICS MARKET DYNAMICS
• FIGURE 8. LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. LYMPHOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. LYMPHOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. LYMPHOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. LYMPHOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 5. LYMPHOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 7. LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. LYMPHOMA THERAPEUTICS MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. LYMPHOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. LYMPHOMA THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. LYMPHOMA THERAPEUTICS MARKET SIZE, BY STEM CELL OR BONE MARROW TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. LYMPHOMA THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. LYMPHOMA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 16. LYMPHOMA THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. LYMPHOMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. LYMPHOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. CANADA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 30. CANADA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 31. CANADA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. CHINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 47. CHINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 48. CHINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. INDIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 50. INDIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 51. INDIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. ITALY LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 102. ITALY LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 103. ITALY LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. POLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 114. POLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 115. POLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. QATAR LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 117. QATAR LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 118. QATAR LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. LYMPHOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 147. LYMPHOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 148. LYMPHOMA THERAPEUTICS MARKET LICENSE & PRICING

The Global Lymphoma Therapeutics Market is forecasted to grow significantly, with a projected USD 9,235.55 million in 2023 at a CAGR of 14.11% and expected to reach a staggering USD 23,371.27 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Lymphoma Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Lymphoma Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Treatment, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, Stem Cell or Bone Marrow Transplantation, Surgery, and Targeted Therapy. The Immunotherapy is further studied across Chimeric Antigen Receptor T-Cell Therapy, Immune Checkpoint Inhibitors, and Monoclonal Antibodies. The Immunotherapy is projected to witness significant market share during forecast period.

Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals. The Ambulatory Surgical Centers is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Lymphoma Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Lymphoma Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Lymphoma Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Lymphoma Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Lymphoma Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Lymphoma Therapeutics Market?

6. What is the market share of the leading vendors in the Global Lymphoma Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Lymphoma Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Lymphoma Therapeutics Market, by Treatment, 2022 vs 2030
• 4.3. Lymphoma Therapeutics Market, by End User, 2022 vs 2030
• 4.4. Lymphoma Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of different types of cancer
    • 5.1.1.2. Increasing adoption of premium products such as immune checkpoint inhibitors and Keytruda
    • 5.1.1.3. Recent approval of several novel therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing co-promotion and commercialization
    • 5.1.3.2. Extensive growth in R&D practices
  • 5.1.4. Challenges
    • 5.1.4.1. Patent expiry of drugs
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Lymphoma Therapeutics Market, by Treatment

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Immunotherapy
  • 6.3.1. Chimeric Antigen Receptor T-Cell Therapy
  • 6.3.2. Immune Checkpoint Inhibitors
  • 6.3.3. Monoclonal Antibodies
• 6.4. Radiation Therapy
• 6.5. Stem Cell or Bone Marrow Transplantation
• 6.6. Surgery
• 6.7. Targeted Therapy

7. Lymphoma Therapeutics Market, by End User

• 7.1. Introduction
• 7.2. Ambulatory Surgical Centers
• 7.3. Clinics
• 7.4. Hospitals

8. Americas Lymphoma Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Lymphoma Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Lymphoma Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing